VIDEO: Obeticholic acid improves survival in primary biliary cholangitis

VIDEO: Obeticholic acid improves survival in primary biliary cholangitis

In a video exclusive, Gideon Hirschfield, PhD, FRCP, of the University of Toronto, reported the potential of obeticholic acid for improving transplant-free survival among patients with primary biliary cholangitis.Specific data from the long-term extension of the phase 3 POISE trial revealed, compared with primary biliary cholangitis (PBC) natural history data from the Global PBC and UK-PBC databases, patients treated with obeticholic acid had a 77% to 80% lower risk for death or liver transplant.“The top-line, take-home messages for the study were one, that we could create so-calledRead More

Share on facebook
Share on twitter
Share on linkedin